Results 151 to 160 of about 29,580 (292)

<p>Ruxolitinib In The Treatment Of Polycythemia Vera: An Update On Health-Related Quality Of Life And Patient-Reported Outcomes</p>

, 2019
Shashank Cingam, Lainey Flatow-Trujillo, Leslie A. Andritsos, Cecilia Arana Yi   +3 more
openalex   +2 more sources

Cytochrome B5 type A alleviates HCC metastasis via regulating STOML2 related autophagy and promoting sensitivity to ruxolitinib [PDF]

, 2022
Hongrui Guo, Shuhang Liang, Yan Wang, Shuo Zhou, Dalong Yin, Shugeng Zhang, Jizhou Wang, Dehai Wu, Kun Ma, Yufeng Liu, Linmao Sun, Changyong Ji, Xianying Li, Huanran Zhou, Guangchao Yang, Xinyu Guo, Tianming Cui, Zihao Li, Yao Liu, Jiabei Wang, Lianxin Liu   +20 more
openalex   +1 more source

Pharmacovigilance‐Based Identification and Mechanistic Exploration of Periodontitis‐Related Drugs

Journal of Clinical Periodontology, Volume 53, Issue 1, Page 117-126, January 2026.
ABSTRACT Background Periodontitis is a common chronic inflammatory disease. However, drug‐related risks and underlying molecular mechanisms remain underexplored from large real‐world data. Methods We first mined the US Food and Drug Administration Adverse Event Reporting System (FAERS) database to identify drugs disproportionately associated with ...
Wuda Huoshen, Junkai Xiong, Xunmi Ma, Heng Wang, Panyu Cheng, Xinyu Chen, Ge Shuai, Yi Chen, Xinyue Zhang, Chen Sun, Chunhui Li, Rui Shi   +11 more
wiley   +1 more source

JAK-2 inhibitors and allogeneic transplant in myelofibrosis [PDF]

, 2015
7The activation of the JAK1/JAK2 pathway plays a crucial role in the pathogenesis of myelofibrosis. Treatment with the JAK2 inhibitor ruxolitinib demonstrated to reduce splenomegaly and symptoms in patients affected by myelofibrosis, leading to a ...
Cigana, C, De Marchi, R, Fanin, Renato, Lazzarotto, D, Patriarca, Francesca, Perali, G, Sperotto, A   +6 more
core  

Hypertriglyceridemia-Induced Acute Pancreatitis Associated with Ruxolitinib for Hemophagocytic Lymphohistiocytosis: A Case Report

Case Reports in Oncological Medicine
Ruxolitinib is a Janus kinase inhibitor that has been associated with lipid abnormalities, including a 15% incidence of hypertriglyceridemia. We describe a case of a 37-year-old man with refractory T-cell lymphoma treated with ruxolitinib for ...
Sarah Medina, Leslie A. Ynalvez, Hyeon-Ju Ryoo Ali, Maria E. Cabanillas, Ihab Hamzeh, Salil Kumar, Nicolas Palaskas, Anita Deswal, Shaden Khalaf   +8 more
doaj   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, Volume 19, Issue 12, Page 3706-3728, December 2025.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Supplementary Figure 3 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy

, 2023
Mohammed G. Ghonime, Kevin A. Cassady
openalex   +1 more source

PS1243 JAK‐INHIBITION WITH RUXOLITINIB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A PHASE II, OPEN LABEL, MULTICENTER CLINICAL TRIAL (JERICHO)

, 2019
Silke Gillessen, Annette Pluetschow, Vladan Vučinić, Helmut Ostermann, Carsten Kobe, Paul J. Broeckelmann, Michael Fuchs, Jesko Momotow, Peter Borchmann, Andreas Engert, Bastian von Tresckow   +10 more
openalex   +1 more source

Nanographene Oxide Attenuates Acute GVHD by Modulating Macrophage Polarization in a Xenogeneic Mouse Model

Advanced Science, Volume 12, Issue 45, December 4, 2025.
Nanographene oxide (NGO) attenuates graft‐versus‐host disease (GVHD) severity by inhibiting STAT1‐mediated M1 macrophage polarization and suppressing T‐cell activation. NGO‐primed macrophages (NGO‐Mac) further enhance regulatory T‐cell induction via IL‐10. Both NGO and NGO‐Mac therapies mitigate inflammation and immune pathology, offering cell‐free and
Aaron Yu, Hyun Sung Park, Dong‐Hoon Chae, Jae Han Park, Jiyoung Heo, Keonwoo Cho, Jiho Kim, Hyewon Lee, Sueyeon Jee, Chanwoo Kim, Soon Won Choi, Jaechul Ryu, Eun‐Hye Hur, Yunsuk Choi, Eun‐Ji Choi, Mi‐Kyung Oh, Hwa‐Yong Lee, Je‐Hwan Lee, Kyung‐Rok Yu   +18 more
wiley   +1 more source

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) [PDF]

, 2018
Nikolas von Bubnoff, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke, Robert Zeiser   +7 more
openalex   +1 more source